SenoRx settles with Suros
This article was originally published in The Gray Sheet
Executive Summary
Firm agrees to remove the transverse slot from the cutter of its EnCor breast biopsy device without admission of liability or payments to resolve a patent dispute with Suros Surgical Systems. To avoid further litigation, which has been ongoing since Suros filed suit in the U.S. District Court for the Southern District of Indiana in February 2005, the technology, in its original form, cannot be sold after Oct. 31, 2006. The modification will have no impact on the EnCor device, SenoRx maintains...
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.